J
Jean-Jacques Kiladjian
Researcher at University of Paris
Publications - 381
Citations - 15910
Jean-Jacques Kiladjian is an academic researcher from University of Paris. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 51, co-authored 303 publications receiving 12479 citations. Previous affiliations of Jean-Jacques Kiladjian include French Institute of Health and Medical Research & Paris Diderot University.
Papers
More filters
Journal ArticleDOI
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire N. Harrison,Jean-Jacques Kiladjian,Haifa Kathrin Al-Ali,Heinz Gisslinger,Roger J. Waltzman,Viktoriya Stalbovskaya,Mari McQuitty,Deborah S. Hunter,Richard S. Levy,Laurent Knoops,Francisco Cervantes,Alessandro M. Vannucchi,Tiziano Barbui,Giovanni Barosi +13 more
TL;DR: Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.
Journal ArticleDOI
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin
Nicole Casadevall,Joelle Nataf,Beatrice Viron,Amir Kolta,Jean-Jacques Kiladjian,Philippe Martin-Dupont,Patrick Michaud,Thomas Papo,Valérie Ugo,Irène Teyssandier,Bruno Varet,Patrick Mayeux +11 more
TL;DR: In this article, the authors identified 13 patients in whom pure red-cell aplasia developed during treatment with recombinant human erythropoietin (epoetin), and investigated whether there was an immunologic basis for the anemia in these patients.
Journal ArticleDOI
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui,Giovanni Barosi,Gunnar Birgegård,Francisco Cervantes,Guido Finazzi,Martin Griesshammer,Claire N. Harrison,Hans Carl Hasselbalch,Rüdiger Hehlmann,Ronald Hoffman,Jean-Jacques Kiladjian,Kröger N,Ruben A. Mesa,Mary Frances McMullin,Animesh Pardanani,Francesco Passamonti,Alessandro M. Vannucchi,Andreas Reiter,Richard T. Silver,Srdan Verstovsek,Ayalew Tefferi +20 more
TL;DR: A review of critical concepts and recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues are presented.
Journal ArticleDOI
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi,Jean-Jacques Kiladjian,Martin Griesshammer,Tamás Masszi,Simon Durrant,Francesco Passamonti,Claire N. Harrison,Fabrizio Pane,Pierre Zachee,Ruben A. Mesa,Shui He,Mark M. Jones,William M. Garrett,Jingjin Li,Ulrich Pirron,Dany Habr,Srdan Verstovsek +16 more
TL;DR: In patients who had an inadequate response to or had unacceptable side effects from hydroxyurea, ruxolitinib was superior to standard therapy in controlling the hematocrit, reducing the spleen volume, and improving symptoms associated with polycythemia vera.
Journal ArticleDOI
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian,Bruno Cassinat,Sylvie Chevret,Pascal Turlure,Nathalie Cambier,Murielle Roussel,Sylvia Bellucci,Bernard Grandchamp,Christine Chomienne,Pierre Fenaux +9 more
TL;DR: Results show that pegylated IFN-alpha-2a yields high rates of hematologic and molecular response in PV with limited toxicity, and could even eliminate the JAK2 mutated clone in selected cases.